Hydroxyurea Optimization through Precision Study (HOPS) is a prospective, multi-center,
randomized trial that will directly compare a novel, individualized dosing strategy of
hydroxyurea to standard weight-based dosing for children with SCA. The primary objective of
the study is to evaluate whether a pharmacokinetics-based starting hydroxyurea dose thieves
superior fetal hemoglobin response to to standard weight-based initial dosing. Patients will
be recruited from the pediatric sickle cell clinic at Cincinnati Children's Hospital Medical
Center and from additional pediatric sickle cell centers within the United States.